Global Hematological Malignancies Emerging Therapeutics Market to Reach $43,966.8 Million by 2031

Global Information, Inc. [JASDAQ 4171]

The hematological malignancies emerging therapeutics market growth has been primarily attributed to major drivers in this market, such as growing prevalence of hematological malignancies, favorable regulatory environment, and increase in adoption of precision medicine in the field of hematological malignancies. However, there are significant challenges restraining the market growth. These challenges include the high cost hindering the adoption rate, unfavorable reimbursement scenario, and safety concerns pertaining to severe adverse effects.

The global hematological malignancies emerging therapeutics industry analysis by BIS Research projects the market to grow at a significant CAGR of 14.20% during the forecast period 2021-2031. The hematological malignancies emerging therapeutics market was valued at $11,652.5 million in 2021 and is expected to generate $43,966.8 million in 2031.

Major players in the industry

AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.

Market Segmentation

Marketed Drugs – Monoclonal Antibodies and CAR-T Cell Therapy
Potential Pipeline Products – Monoclonal Antibodies and CAR-T Cell Therapy
Indication – Leukemia, Lymphoma, and Multiple Myeloma

Market Growth Drivers

Growing Prevalence of Hematological Malignancies
Favorable Regulatory Environment
Increase in Adoption of Precision Medicine in the Field of Hematological Malignancies

Continue reading: https://www.giiresearch.com/report/bis1062846-hematological-malignancies-emerging-therapeutics.html 

Contact: marketing@giiresearch.com 

Tags: Market Research, COVID-19 Impact, Marketed Drugs Research, Pipeline Products Research See Campaign: https://www.giiresearch.com/report/bis1062846-hematological-malignancies-emerging-therapeutics.html

Contact Information:

Global Information, Inc. [JASDAQ 4171] https://www.giiresearch.com/ Toll Free (US): +1-866-353-3335 Outside US: +1-860-674-8796 Europe (Belgium): +32-2-535-7543 Email: marketing@giiresearch.com

Tags:
Financial Content, PR-Wirein, Reportedtimes, iCN Internal Distribution, Extended Distribution, Research Newswire, English